ADMA Biologics Inc (NASDAQ:ADMA) – Analysts at Jefferies Financial Group increased their FY2023 EPS estimates for shares of ADMA Biologics in a research report issued on Wednesday, November 6th. Jefferies Financial Group analyst A. Petrone now forecasts that the biotechnology company will post earnings per share of $1.50 for the year, up from their previous forecast of $1.48.
ADMA Biologics (NASDAQ:ADMA) last issued its quarterly earnings results on Wednesday, November 6th. The biotechnology company reported ($0.19) EPS for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.04. ADMA Biologics had a negative return on equity of 214.26% and a negative net margin of 323.54%. The firm had revenue of $7.22 million for the quarter, compared to analysts’ expectations of $5.71 million.
Several other brokerages have also commented on ADMA. BidaskClub upgraded ADMA Biologics from a “hold” rating to a “buy” rating in a research report on Wednesday. Dawson James lowered ADMA Biologics from a “buy” rating to a “neutral” rating and set a $4.00 price objective on the stock. in a research report on Monday, August 12th. ValuEngine upgraded ADMA Biologics from a “hold” rating to a “buy” rating in a research report on Friday, September 20th. Finally, Maxim Group set a $12.00 price objective on ADMA Biologics and gave the company a “buy” rating in a research report on Monday, October 21st. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. ADMA Biologics has an average rating of “Buy” and an average target price of $10.20.
Shares of NASDAQ ADMA traded down $0.21 during trading on Friday, reaching $4.31. 940,100 shares of the stock traded hands, compared to its average volume of 884,660. The company has a debt-to-equity ratio of 1.79, a current ratio of 10.26 and a quick ratio of 7.93. The stock has a market capitalization of $304.89 million, a P/E ratio of -2.97 and a beta of 2.70. The company has a 50-day moving average of $4.59 and a 200-day moving average of $4.26. ADMA Biologics has a 52-week low of $2.08 and a 52-week high of $6.31.
Several institutional investors have recently made changes to their positions in ADMA. H D Vest Advisory Services increased its position in shares of ADMA Biologics by 35.0% during the 2nd quarter. H D Vest Advisory Services now owns 135,050 shares of the biotechnology company’s stock valued at $523,000 after purchasing an additional 35,000 shares during the last quarter. Private Advisors LLC bought a new position in ADMA Biologics during the 2nd quarter worth approximately $41,000. Charles Schwab Investment Management Inc. grew its position in ADMA Biologics by 49.2% during the 2nd quarter. Charles Schwab Investment Management Inc. now owns 65,180 shares of the biotechnology company’s stock worth $253,000 after acquiring an additional 21,480 shares during the last quarter. Bank of New York Mellon Corp grew its position in ADMA Biologics by 35.5% during the 2nd quarter. Bank of New York Mellon Corp now owns 82,176 shares of the biotechnology company’s stock worth $317,000 after acquiring an additional 21,545 shares during the last quarter. Finally, Northern Trust Corp grew its position in ADMA Biologics by 14.4% during the 2nd quarter. Northern Trust Corp now owns 299,248 shares of the biotechnology company’s stock worth $1,158,000 after acquiring an additional 37,677 shares during the last quarter. Hedge funds and other institutional investors own 59.10% of the company’s stock.
About ADMA Biologics
ADMA Biologics, Inc, a biopharmaceutical and specialty immunoglobulin company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases. Its lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical trials for the treatment of primary immune deficiency disease.
Read More: Growth Stocks
Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with MarketBeat.com's FREE daily email newsletter.